1
|
Miljoen H, Favere K, Van De Heyning C, Corteville B, Dausin C, Herbots L, Teulingkx T, Bekhuis Y, Lyssens M, Bogaert J, Heidbuchel H, Claessen G. Low rates of myocardial fibrosis and ventricular arrhythmias in recreational athletes after SARS-CoV-2 infection. Front Cardiovasc Med 2024; 11:1372028. [PMID: 38628312 PMCID: PMC11018940 DOI: 10.3389/fcvm.2024.1372028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Accepted: 02/26/2024] [Indexed: 04/19/2024] Open
Abstract
Introduction High rates of cardiac involvement were reported in the beginning of the coronavirus disease 2019 (COVID-19) pandemic. This led to anxiety in the athletic population. The current study was set up to assess the prevalence of myocardial fibrosis and ventricular arrhythmias in recreational athletes with the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods Consecutive adult recreational athletes (≥18 years old, ≥4 h of mixed type or endurance sports/week) underwent systematic cardiac evaluation after a prior confirmed COVID-19 infection. Evaluation included clinical history, electrocardiogram (ECG), 5-day Holter monitoring, and cardiac magnetic resonance (CMR) imaging with simultaneous measurement of high-sensitive cardiac Troponin I. Data from asymptomatic or mildly symptomatic athletes (Group 1) were compared with those with moderate to severe symptoms (Groups 2-3). Furthermore, a comparison with a historical control group of athletes without COVID-19 (Master@Heart) was made. Results In total, 35 athletes (18 Group 1, 10 female, 36.9 ± 2.2 years, mean 143 ± 20 days following diagnosis) were evaluated. The baseline characteristics for the Group 1 and Groups 2-3 athletes were similar. None of the athletes showed overt myocarditis on CMR based on the updated Lake Louise criteria for diagnosis of myocarditis. The prevalence of non-ischemic late gadolinium enhancement [1 (6%) Group 1 vs. 2 (12%) Groups 2-3; p = 0.603] or ventricular arrhythmias [1 Group 1 athlete showed non-sustained ventricular tachycardia (vs. 0 in Groups 2-3: p = 1.000)] were not statistically different between the groups. When the male athletes were compared with the Master@Heart athletes, again no differences regarding these criteria were found. Conclusion In our series of recreational athletes with prior confirmed COVID-19, we found no evidence of ongoing myocarditis, and no more detection of fibrosis or ventricular arrhythmias than in a comparable athletic pre-COVID cohort. This points to a much lower cardiac involvement of COVID-19 in athletes than originally suggested.
Collapse
Affiliation(s)
- Hielko Miljoen
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
- Research Group Cardiovascular Diseases, Department GENCOR, University of Antwerp, Antwerp, Belgium
| | - Kasper Favere
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
- Research Group Cardiovascular Diseases, Department GENCOR, University of Antwerp, Antwerp, Belgium
- Department of Internal Medicine, Ghent University, Ghent, Belgium
| | - Caroline Van De Heyning
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
- Research Group Cardiovascular Diseases, Department GENCOR, University of Antwerp, Antwerp, Belgium
| | - Ben Corteville
- Department of Cardiology, Jan Palfijn Hospital, Ghent, Belgium
| | - Christophe Dausin
- Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, Belgium
| | - Lieven Herbots
- Department of Cardiology, Hartcentrum, Jessa Hospital, Hasselt, Belgium
- Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
| | | | - Youri Bekhuis
- Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
- Department of Cardiology, Leuven University Hospitals, Leuven, Belgium
- Department of Cardiovascular Sciences, Faculty of Medicine, KU Leuven, Leuven, Belgium
| | - Malou Lyssens
- Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, Belgium
| | - Jan Bogaert
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium
| | - Hein Heidbuchel
- Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium
- Research Group Cardiovascular Diseases, Department GENCOR, University of Antwerp, Antwerp, Belgium
- Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
| | - Guido Claessen
- Department of Cardiology, Hartcentrum, Jessa Hospital, Hasselt, Belgium
- Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium
| |
Collapse
|
2
|
De Bosscher R, Claeys M, Dausin C, Goetschalckx K, Claus P, Herbots L, Ghekiere O, Van De Heyning C, Paelinck BP, Janssens K, Wright L, Flannery MD, La Gerche A, Willems R, Heidbuchel H, Bogaert J, Claessen G. Three-dimensional echocardiography of the athlete's heart: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 2023; 39:295-306. [PMID: 36151432 DOI: 10.1007/s10554-022-02726-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 09/03/2022] [Indexed: 01/28/2023]
Abstract
Three-dimensional echocardiography (3DE) is the most accurate cardiac ultrasound technique to assess cardiac structure. 3DE has shown close correlation with cardiac magnetic resonance imaging (CMR) in various populations. There is limited data on the accuracy of 3DE in athletes and its value in detecting alterations during follow-up. Indexed left and right ventricular end-diastolic volume (LVEDVi, RVEDVi), end-systolic volume, ejection fraction (LVEF, RVEF) and left ventricular mass (LVMi) were assessed by 3DE and CMR in two-hundred and one competitive endurance athletes (79% male) from the Pro@Heart trial. Sixty-four athletes were assessed at 2 year follow-up. Linear regression and Bland-Altman analyses compared 3DE and CMR at baseline and follow-up. Interquartile analysis evaluated the agreement as cardiac volumes and mass increase. 3DE showed strong correlation with CMR (LVEDVi r = 0.91, LVEF r = 0.85, LVMi r = 0.84, RVEDVi r = 0.84, RVEF r = 0.86 p < 0.001). At follow up, the percentage change by 3DE and CMR were similar (∆LVEDVi r = 0.96 bias - 0.3%, ∆LVEF r = 0.94, bias 0.7%, ∆LVMi r = 0.94 bias 0.8%, ∆RVESVi r = 0.93, bias 1.2%, ∆RVEF r = 0.87 bias 0.4%). 3DE underestimated volumes (LVEDVi bias - 18.5 mL/m2, RVEDVi bias - 25.5 mL/m2) and the degree of underestimation increased with larger dimensions (Q1vsQ4 LVEDVi relative bias - 14.5 versus - 17.4%, p = 0.016; Q1vsQ4 RVEDVi relative bias - 17 versus - 21.9%, p = 0.005). Measurements of cardiac volumes, mass and function by 3DE correlate well with CMR and 3DE accurately detects changes over time. 3DE underestimates volumes and the relative bias increases with larger cardiac size.
Collapse
Affiliation(s)
- Ruben De Bosscher
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. .,Department of Cardiology, University Hospitals Leuven, Leuven, Belgium. .,Department of Cardiovascular Medicine, University Hospitals Leuven, B-3000, Leuven, Belgium.
| | - Mathias Claeys
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.,Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
| | | | | | - Piet Claus
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
| | - Lieven Herbots
- Department of Cardiology, Hartcentrum, Jessa Ziekenhuis, Hasselt, Belgium.,REVAL/BIOMED, Hasselt University, Diepenbeek, Belgium
| | - Olivier Ghekiere
- REVAL/BIOMED, Hasselt University, Diepenbeek, Belgium.,Department of Radiology, Jessa Ziekenhuis, Hasselt, Belgium
| | - Caroline Van De Heyning
- Department of Cardiovascular Sciences, University of Antwerp, Antwerp, Belgium.,Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
| | - Bernard P Paelinck
- Department of Cardiovascular Sciences, University of Antwerp, Antwerp, Belgium.,Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
| | - Kristel Janssens
- Department of Cardiology, Baker Heart and Diabetes Institute, Melbourne, Australia
| | - Leah Wright
- Department of Cardiology, Baker Heart and Diabetes Institute, Melbourne, Australia
| | | | - André La Gerche
- Department of Cardiology, Baker Heart and Diabetes Institute, Melbourne, Australia
| | - Rik Willems
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.,Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
| | - Hein Heidbuchel
- Department of Cardiovascular Sciences, University of Antwerp, Antwerp, Belgium.,Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium
| | - Jan Bogaert
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium
| | - Guido Claessen
- Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.,Department of Cardiology, University Hospitals Leuven, Leuven, Belgium
| | | |
Collapse
|
3
|
Palazzini M, Lupi L, Ammirati E, Giannattasio C, Soriano F, Pedrotti P, Briguglia D, Mapelli M, Campodonico J, Agostoni P, Leonardi S, Turco A, Guida S, Peretto G, Sala S, Camici PG, Marzo F, Grosu A, Senni M, Turrini F, Bramerio M, Marini M, Matassini MV, Rizzo S, Basso C, De Gaspari M, Hendren NS, Schmidt M, Bochaton T, Piriou N, Ubarri A, Van De Heyning C, Sole AA, Cannatà A, Salamanca J, Lehtonen J, Huang F, Adler ED, Metra M. 132 PREVALENCE CHARACTERISTICS AND OUTCOMES OF COVID 19 ASSOCIATED ACUTE MYOCARDITIS. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartjsupp/suac121.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Abstract
Background
Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19–associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe.
Methods
A total of 112 patients with suspected AM from 56963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19–associated AM.
Results
AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19–associated pneumonia. Twenty- one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia (P=0.044). During hospitalization, left ventricular ejection fraction, assessed by echocardiography, improved from a median of 40% on admission to 55% at discharge (n=47; P<0.0001) similarly in patients with or without pneumonia. Corticosteroids were frequently administered (55.5%).
Conclusions
AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.
Collapse
Affiliation(s)
- Matteo Palazzini
- De Gasperis Cardio Center And Transplant Center , Niguarda, Milano
| | - Laura Lupi
- Institute Of Cardiology, Department Of Medical And Surgical Specialties, Radiological Science And Public Healt, University Of Brescia
| | - Enrico Ammirati
- De Gasperis Cardio Center And Transplant Center , Niguarda, Milano
| | | | | | | | | | - Massimo Mapelli
- Centro Cardiologico Monzino, IRCCS Milano Italy, Department Of Clinical Sciences And Community Healt Cardiovascular Section, University Of Milano , Milano
| | - Jeness Campodonico
- Centro Cardiologico Monzino, IRCCS Milano Italy, Department Of Clinical Sciences And Community Healt Cardiovascular Section, University Of Milano , Milano
| | - Piergiuseppe Agostoni
- Centro Cardiologico Monzino, IRCCS Milano Italy, Department Of Clinical Sciences And Community Healt Cardiovascular Section, University Of Milano , Milano
| | - Sergio Leonardi
- Coronary Care Unit And Laboratory Of Clinical And Experimental Cardiology Fondazione Irccs Policlinico S Matteo
| | - Annalisa Turco
- Coronary Care Unit And Laboratory Of Clinical And Experimental Cardiology Fondazione Irccs Policlinico S Matteo
| | - Stefania Guida
- Coronary Care Unit And Laboratory Of Clinical And Experimental Cardiology Fondazione Irccs Policlinico S Matteo
| | - Giovanni Peretto
- San Raffaele Hospital And Vita Salute University , Milano , Italy
| | - Simone Sala
- San Raffaele Hospital And Vita Salute University , Milano , Italy
| | - Paolo G Camici
- San Raffaele Hospital And Vita Salute University , Milano , Italy
| | | | - Aurelia Grosu
- Cardiovascular Department , Asst Papa Giovanni Xxiii, Bergamo , Italy
| | - Michele Senni
- Cardiovascular Department , Asst Papa Giovanni Xxiii, Bergamo , Italy
| | | | - Manuela Bramerio
- Department Of Histopathology, Niguarda Hospital , Milano , Italy
| | - Marco Marini
- Cardiology Division, Cardiovascular Department , Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Umberto I, Gm Lancisi, G Salesi, Ancona , Italy
| | - Maria Vittoria Matassini
- Cardiology Division, Cardiovascular Department , Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Umberto I, Gm Lancisi, G Salesi, Ancona , Italy
| | - Stefania Rizzo
- Cardiovascular Patology Unit, Azienda Ospedaliera, Department Of Cardiac, Thoracic, Vascular Science And Public Healt, University Of Padua , Italy
| | - Cristina Basso
- Cardiovascular Patology Unit, Azienda Ospedaliera, Department Of Cardiac, Thoracic, Vascular Science And Public Healt, University Of Padua , Italy
| | - Monica De Gaspari
- Cardiovascular Patology Unit, Azienda Ospedaliera, Department Of Cardiac, Thoracic, Vascular Science And Public Healt, University Of Padua , Italy
| | - Nicholas S Hendren
- Division Of Cardiology, Department Of Internal Medicine, University Of Texas Southwestern Medical Center , Dallas
| | - Matthieu Schmidt
- Sorbonne Universitè, Umrs 1166, Institute Of Cardiometabolism And Nutrition, Service De Medecine Intensive-Reanimation, Institute De Cardiologie Assistant Publique-Hopitaux De Paris Hopital Pitie-Salpetriere , France
| | - Thomas Bochaton
- Urgences Et Soins Critiques Cardiologiques , Hopital Cardiologique, Hospices Civils De Lyon, Bron , France
| | - Nicolas Piriou
- Universite Nantes, Chu Nantes, Centre National De La Recherche Scientifique, Institute National De La Santè Et De La Recherche Medicale , France
| | - Aitor Ubarri
- Departamento De Cardiologia, Hospital Clinico Universitario , Valladolid , Spain
| | - Caroline Van De Heyning
- Department Of Cardiology, Antwerp University Hospital, Genetics, Pharmacology And Physiopathology Of Heart, Blood And Vessels And Skeleton Research Group, Antwerp University , Belgium
| | - Albert Ariza Sole
- Cardiology Department, Bellvitge University Hospital , Bioheart, Grup De Malalties Cardiovasculars, Institut De Investigacio Biomedica De Bellvitge, L’hospotalet Del Llobregat, Barcelona , Spain
| | - Antonio Cannatà
- School Of Cardiovascular Medicine And Science, King’s College, London, British Heart Foundation, Centre Of Excellence, James Black Centre , United Kingdom
| | - Jorge Salamanca
- Cardiology Department, Hospital Universitario De La Princesa , Madrid , Spain
| | - Jukka Lehtonen
- Heart And Lung Center, Department Of Cardiology, Helsinki University Hospital,Finland
| | - Florent Huang
- Service De Cardiologie , Hopital Foch, Suresnes , France
| | - Eric D Adler
- Division Of Cardiology, Department Of Medicine, University Of California San Diego
| | - Marco Metra
- Institute Of Cardiology, Department Of Medical And Surgical Specialties, Radiological Science And Public Healt, University Of Brescia
| |
Collapse
|
4
|
Darden D, Ammirati E, Brambatti M, Lin A, Hsu JC, Shah P, Perna E, Cikes M, Gjesdal G, Potena L, Masetti M, Jakus N, Van De Heyning C, De Bock D, Brugts JJ, Russo CF, Veenis JF, Rega F, Cipriani M, Frigerio M, Liviu K, Hong KN, Adler E, Braun OÖ. Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. Int J Cardiol 2021; 340:26-33. [PMID: 34437934 DOI: 10.1016/j.ijcard.2021.08.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 08/01/2021] [Accepted: 08/20/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND There is conflicting observational data on the survival benefit cardiac implantable electronic devices (CIED) in patients with LVADs. METHODS Patients in whom an LVAD was implanted between January 2008 and April 2017 in the multinational Trans-Atlantic Registry on VAD and Transplant (TRAViATA) registry were separated into four groups based on the presence of CIED prior to LVAD implantation: none (n = 146), implantable cardiac defibrillator (ICD) (n = 239), cardiac resynchronization without defibrillator (CRT-P) (n = 28), and CRT with defibrillator (CRT-D) (n = 111). RESULTS A total of 524 patients (age 52 years ±12, 84.4% male) were followed for 354 (interquartile range: 166-701) days. After multivariable adjustment, there were no differences in survival across the groups. In comparison to no device, only CRT-D was associated with late right ventricular failure (RVF) (hazard ratio 2.85, 95% confidence interval [CI] 1.42-5.72, p = 0.003). There was no difference in risk of early RVF across the groups or risk of ICD shocks between those with ICD and CRT-D. CONCLUSION In a multinational registry of patients with LVADs, there were no differences in survival with respect to CIED subtype. However, patients with a pre-existing CRT-D had a higher likelihood of late RVF suggesting significant long-term morbidity in those with devices capable of LV‑lead pacing post LVAD implantation.
Collapse
Affiliation(s)
- Douglas Darden
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
| | - Enrico Ammirati
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy
| | - Michela Brambatti
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Andrew Lin
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Jonathan C Hsu
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Palak Shah
- Heart Failure, Mechanical Circulatory Support, and Transplantation, Inova Heart and Vascular Institute, Falls Church, Washington, VA, USA
| | - Enrico Perna
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy
| | - Maja Cikes
- Division of Cardiology, Department of Medicine, University Hospital, Zagreb, Croatia
| | - Grunde Gjesdal
- Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden
| | - Luciano Potena
- Division of Cardiology, Department of Medicine, Academic Hospital S. Orsola-Malpighi, Bologna, Italy
| | - Marco Masetti
- Division of Cardiology, Department of Medicine, Academic Hospital S. Orsola-Malpighi, Bologna, Italy
| | - Nina Jakus
- Division of Cardiology, Department of Medicine, University Hospital, Zagreb, Croatia
| | | | - Dina De Bock
- Department of Cardiology and Cardiac Surgery, Antwerp University Hospital, Edegem, Belgium
| | - Jasper J Brugts
- Division of Cardiology, Department of Medicine, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, Netherlands
| | - Claudio F Russo
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy
| | - Jesse F Veenis
- Division of Cardiology, Department of Medicine, Erasmus MC, University Medical Center Rotterdam, Thoraxcenter, Rotterdam, Netherlands
| | - Filip Rega
- Division of Cardiology, Department of Medicine, University Hospital, Leuven, Belgium
| | - Manlio Cipriani
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy
| | - Maria Frigerio
- De Gasperis Cardio Center and Transplant Center, Niguarda Hospital, Milano, Italy
| | - Klein Liviu
- Division of Cardiology, Department of Medicine, University of California San Francisco, CA, USA
| | - Kimberly N Hong
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Eric Adler
- Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA
| | - Oscar Ö Braun
- Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden
| |
Collapse
|
5
|
Darden D, Ammirati E, Brambatti M, Hsu JC, Braun O, Shah P, Van De Heyning C, Perna E, Cikes M, Gjesdal G, Potena L, Marco M, Jakus N, De Bock D, Brugts JJ, Russo C, Veenis J, Rega F, Klein L, Pretorius G, Cipriani M, Frigerio M, Adler E. ASSOCIATION OF CARDIAC RESYNCHRONIZATION THERAPY WITH MORTALITY, DEFIBRILLATION, AND RIGHT VENTRICULAR FAILURE IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICES. J Am Coll Cardiol 2020. [DOI: 10.1016/s0735-1097(20)31502-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|